Dr. Wei-Chiang Chen is currently Associate Director in BioProcess Analytics focusing on gene therapy CMC development at Genomic Medicine Unit of Sanofi. Wei-Chiang is leading a group of scientists to develop high throughput analytical assays (mostly LC and CE based methods) supporting process development and manufacturing of gene therapy products, including of both viral and non-viral gene therapy. Also, Wei-Chiang manages many CMC analytical activities for various gene therapy products for Sanofi. Prior to joining Sanofi, Wei-Chiang worked at different companies, such as Flexion Therapeutics, Solid Biosciences, Biogen, and Immunogen. He had extensive experience in assay development and process development for biologics, such as monoclonal antibodies, fusion proteins, AAV, and adenovirus, etc. Wei-Chiang earned his Ph.D. in Chemical and Biomolecular Engineering from the Johns Hopkins University, a M.S in Chemical Engineering from University of Florida and a B.S. in Chemical Engineering from National Cheng Kung University in Taiwan.